文献速递血管炎

嗜酸性肉芽肿性多血管炎的心脏受累:急性嗜酸性心肌炎与慢性炎症性心肌病

Cardiac involvement in eosinophilic granulomatosis with polyangiitis: acute eosinophilic myocarditis and chronic inflammatory cardiomyopathy.
PubMed 文献 · Rheumatology (Oxford) · 2025-01-01

研究纳入2012至2023年本中心住院及公共数据库的193例EGPA患者,其中心脏受累118例(嗜酸性心肌炎74例、慢性炎症性心肌病44例),对照75例。嗜酸性心肌炎患者肌钙蛋白进一步升高、射血分数降低、ST-T异常更多,预后显著更差,病死率14.86%,2年无事件生存率低于50%。作者提出LATE-EAST诊断评分(7项9分,阈值4分)以区分嗜酸性心肌炎与慢性炎症性心肌病。

要点

  • EGPA心脏受累可分为嗜酸性心肌炎与慢性炎症性心肌病两种亚型。
  • 嗜酸性心肌炎患者病死率14.86%,2年无事件生存率低于50%。
  • LATE-EAST评分以4分为阈值区分嗜酸性心肌炎与慢性炎症性心肌病,AUC 0.85。

核心结论

  • 作者首次提出EGPA心脏受累的不同亚型,嗜酸性心肌炎的识别与治疗有待改善,LATE-EAST评分可有效识别高危嗜酸性心肌炎。
  • 作者认为需要多学科治疗,应及时给予免疫抑制治疗,抗IL-5抗体应在试验中接受检验。

研究设计与样本

  • 纳入2012至2023年本中心住院及公共数据库的EGPA患者,共193例,中心脏受累118例(嗜酸性心肌炎74例、慢性炎症性心肌病44例),对照75例。
  • 根据心肌酶、心脏MRI和心内膜心肌活检结果将患者分为嗜酸性心肌炎组、慢性炎症性心肌病组和对照组,收集并比较临床、实验室、影像结果和预后。

主要发现

  • 从对照组到慢性炎症性心肌病组再到嗜酸性心肌炎组,嗜酸性粒细胞增高(6.12/8.71/10.42 × 10^9/L,P < 0.01),ANCA阳性率降低(41.33/31.82/14.86%,P < 0.01),肺部受累减少(73.33/72.73/43.24%,P = 0.02)。
  • 嗜酸性心肌炎组心肌肌钙蛋白进一步升高(0.27 vs 6.00 ng/ml,P < 0.01),射血分数降低(57.79 vs 33.20%,P < 0.01),ST-T异常更多(41.89 vs 20.45%,P = 0.02)。
  • 嗜酸性心肌炎预后显著更差,病死率14.86%,2年无事件生存率低于50%。
  • LATE-EAST诊断评分共7项9分,以4分为阈值区分嗜酸性心肌炎与慢性炎症性心肌病,受试者工作特征曲线下面积0.85(95% CI 0.78-0.92),敏感度0.78,特异度0.86。

关键数值与推荐

  • LATE-EAST诊断评分共7项9分,以4分为阈值区分嗜酸性心肌炎与慢性炎症性心肌病,受试者工作特征曲线下面积0.85(95% CI 0.78-0.92),敏感度0.78,特异度0.86。

临床怎么用

  • 作者认为需要多学科治疗,应及时给予免疫抑制治疗,抗IL-5抗体应在试验中接受检验。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Currently, cardiac involvement is used to describe all eosinophilic granulomatosis with polyangiitis (EGPA) cardiac problems. However, heterogeneity exists among them. We aimed to depict the disease spectrum of EGPA cardiac involvement and identify the high-risk population. METHODS: We included EGPA patients hospitalized in our centre from 2012 to 2023 and in public databases. Based on the cardiac enzymes, cardiac MRI and endomyocardial biopsy results, the patients were divided into three groups: eosinophilic myocarditis (EGPA-EM), chronic inflammatory cardiomyopathy (EGPA-ICM) and EGPA-Control. Their clinical, laboratory, imaging results and prognoses were collected and compared. RESULTS: A total of 193 EGPA patients were included, 118 with cardiac involvement (74 EGPA-EM, 44 EGPA-ICM) and 75 control. Among EGPA-Control, EGPA-ICM and EGPA-EM, eosinophil increased (6.12/8.71/10.42 × 109/l, P < 0.01), ANCA positivity decreased (41.33/31.82/14.86%, P < 0.01) and lung involvement was reduced (73.33/72.73/43.24%, P = 0.02). In EGPA-EM, cardiac troponin was further elevated (0.27 vs 6.00 ng/ml, P < 0.01), ejection fractions decreased (57.79 vs 33.20%, P < 0.01) while more ST-T abnormality was observed (41.89 vs 20.45%, P = 0.02). The prognosis of EGPA-EM was significantly worse, with a 14.86% death rate and 2-year event-free survival rate below 50%. Furthermore, we proposed a LATE-EAST diagnostic score (7 items, 9 points) to discriminate EGPA-EM from EGPA-ICM using 4 points as threshold [area under the receiver operating characteristic curve 0.85 (95% CI 0.78-0.92), sensitivity 0.78, specificity 0.86]. CONCLUSIONS: We first proposed different subtypes of cardiac involvement in EGPA. Identification and treatment of EGPA-EM needs improvement. LATE-EAST score could recognize the high-risk EGPA-EM effectively. Multi-disciplinary treatment is warranted, immunosuppressive therapy should be given in a timely manner and anti-IL-5 antibodies should be be tested in trials.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Liu X, Zhou Y, Li J, et al. Cardiac involvement in eosinophilic granulomatosis with polyangiitis: acute eosinophilic myocarditis and chronic inflammatory cardiomyopathy. Rheumatology (Oxford). 2025. PMID: 38335934. doi:10.1093/rheumatology/keae085

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。